{"version":"1.0","provider_name":"Substipharm","provider_url":"https:\/\/www.substipharm.com\/es\/","title":"Comunicado de prensa - Substipharm","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"rsmK5mbRhJ\"><a href=\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/\">Comunicado de prensa<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.substipharm.com\/es\/comunicado-de-prensa\/embed\/#?secret=rsmK5mbRhJ\" width=\"600\" height=\"338\" title=\"\u00abComunicado de prensa\u00bb \u2014 Substipharm\" data-secret=\"rsmK5mbRhJ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Comunicado de prensa Substipharm adquiere IMOJEV\u00ae SUBSTIPHARM se enorgullece de anunciar que ha llegado a un acuerdo para adquirir la vacuna contra la Encefalitis Japonesa IMOJEV\u00ae de Sanofi por una cantidad no revelada. IMOJEV\u00ae est\u00e1 indicada para la prevenci\u00f3n de la Encefalitis Japonesa tanto en adultos como en ni\u00f1os, y actualmente se comercializa en Australia, [&hellip;]"}